FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

ARA-290

Cibinetide / Innate Repair Receptor agonist

Immune & Thymic

ARA-290 (also known as cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis or promoting blood cell production. It was developed by Araim Pharmaceuticals to capture the tissue-protective and anti-inflammatory properties of EPO while eliminating the undesirable hematological effects. Clinical trials have focused primarily on painful neuropathies, including diabetic neuropathy and sarcoidosis-associated small fiber neuropathy.

Meccanismo d'azione

Synthetic 11-amino-acid peptide that selectively activates the innate repair receptor (IRR), a heterodimer of EPO receptor and beta common receptor. Promotes tissue protection and repair without erythropoietic effects. Anti-inflammatory via macrophage phenotype switching from M1 to M2.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Clinical trial protocols used 2-8mg subcutaneously or IV daily. Sarcoidosis studies used 5mg IV daily for 28 days. Small fiber neuropathy studies used 4mg subcutaneously 3 times weekly for 28 days.

Note di ricerca

Clinical Research Status

ARA-290 has completed multiple Phase II clinical trials for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy, with results published in peer-reviewed journals showing improvements in corneal nerve fiber density and neuropathic pain scores. The compound received Orphan Drug Designation from the European Medicines Agency for sarcoidosis treatment. Despite promising results, development has progressed slowly, and Phase III trials have not been widely reported as of recent literature.

Key Published Findings

Clinical studies demonstrate that subcutaneous ARA-290 administration increases corneal nerve fiber density (a surrogate marker for small fiber neuropathy) and reduces neuropathic pain in diabetic patients. Research in sarcoidosis patients showed significant improvements in small nerve fiber density, pain scores, and quality of life measures compared to placebo over 28-day treatment periods. Mechanistic studies reveal that IRR activation promotes Schwann cell survival, reduces neuroinflammation, and stimulates axonal regeneration through JAK2/STAT5-independent pathways.

Safety Profile

ARA-290 has demonstrated an excellent safety profile across clinical trials, with no dose-limiting toxicities and adverse event rates comparable to placebo. Unlike EPO, it does not increase hemoglobin levels, platelet counts, or thromboembolic risk, confirming selective IRR activation without erythropoietic receptor engagement. The most common side effects reported include mild injection site reactions and transient headache, with no cardiovascular or hematological safety signals identified.

Comparison to Related Compounds

ARA-290 represents a fundamentally different approach from EPO-derived therapy by targeting the heterocomplex innate repair receptor (EPOR/betaCD131) rather than the homodimeric erythropoietic receptor. Unlike gabapentin or pregabalin which merely modulate pain perception, ARA-290 aims to repair damaged nerve fibers and address the underlying pathology of neuropathy. Compared to other neuroprotective peptides like Cerebrolysin or NGF, ARA-290 has a more defined single-target mechanism through the IRR pathway.

Community Observations

Interest in ARA-290 within research communities centers on its potential as a disease-modifying therapy for neuropathy rather than merely symptomatic treatment. Availability outside of clinical trials is extremely limited, and the compound is not widely accessible through typical peptide suppliers. Patients with small fiber neuropathy from various causes have expressed strong interest in the compound based on published trial results showing objective nerve regeneration.

Semplifichro

~2-3 minutes

Riconcimimento

Sterile saline

Conservazione

Lyofilizzato

Refrigerate 2-8C.

Riconcimato

Use within 24 hours of preparation.

Stato legale USA

Research chemical (in clinical trials)

Anche noto come

CibinetideInnate Repair Receptor agonist

Domande frequenti

Che cos'è ARA-290?

ARA-290 (also known as cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis or promoting blood cell production. It was developed by Araim Pharmaceuticals to capture the tissue-protective and anti-inflammatory properties of EPO while eliminating the undesirable hematological effects. Clinical trials have focused primarily on painful neuropathies, including diabetic neuropathy and sarcoidosis-associated small fiber neuropathy.

Come agisce ARA-290?

Synthetic 11-amino-acid peptide that selectively activates the innate repair receptor (IRR), a heterodimer of EPO receptor and beta common receptor. Promotes tissue protection and repair without erythropoietic effects. Anti-inflammatory via macrophage phenotype switching from M1 to M2.

Qual è lo stato normativo di ARA-290 negli Stati Uniti?

Research chemical (in clinical trials)

Qual è l'emivita di ARA-290?

~2-3 minutes

Con quali altri nomi è noto ARA-290?

Cibinetide, Innate Repair Receptor agonist

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità